Search Results - "Giacoletti, Katherine E. D."

Comparison of the Immunogenicity and Reactogenicity of a Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine in Male and Female Adolescents and Young Adult Women by Block, Stan L, Nolan, Terry, Sattler, Carlos, Barr, Eliav, Giacoletti, Katherine E.D, Marchant, Colin D, Castellsague, Xavier, Rusche, Steven A, Lukac, Suzanne, Bryan, Janine T, Cavanaugh, Paul F., Jr, Reisinger, Keith S, Protocol 016 Study Group

“…Prophylactic vaccination of 16- to 23-year-old females with a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine has been…”
Get full text

Safety and Persistent Immunogenicity of a Quadrivalent Human Papillomavirus Types 6, 11, 16, 18 L1 Virus-Like Particle Vaccine in Preadolescents and Adolescents: A Randomized Controlled Trial by Reisinger, Keith S, Block, Stan L, Lazcano-Ponce, Eduardo, Samakoses, Rudiwilai, Esser, Mark T, Erick, Joanne, Puchalski, Derek, Giacoletti, Katherine E. D, Sings, Heather L, Lukac, Suzanne, Alvarez, Frances B, Barr, Eliav

“…OBJECTIVE:Administration of a quadrivalent HPV-6/11/16/18 vaccine to 16- to 26-year-old women was highly effective in preventing HPV-6/11/16/18-related…”
Get full text

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16–26 Years by Brown, Darron R., Kjaer, Susanne K., Sigurdsson, Kristján, Iversen, Ole-Erik, Hernandez-Avila, Mauricio, Wheeler, Cosette M., Perez, Gonzalo, Koutsky, Laura A., Tay, Eng Hseon, Garcia, Patricía, Ault, Kevin A., Garland, Suzanne M., Leodolter, Sepp, Olsson, Sven-Eric, Tang, Grace W. K., Ferris, Daron G., Paavonen, Jorma, Steben, Marc, Bosch, F. Xavier, Dillner, Joakim, Joura, Elmar A., Kurman, Robert J., Majewski, Slawomir, Muñoz, Nubia, Myers, Evan R., Villa, Luisa L., Taddeo, Frank J., Roberts, Christine, Tadesse, Amha, Bryan, Janine, Lupinacci, Lisa C., Giacoletti, Katherine E. D., Sings, Heather L., James, Margaret, Hesley, Teresa M., Barr, Eliav

“…BackgroundHuman papillomavirus (HPV)–6/11/16/18 vaccine reduces the risk of HPV-6/11/16/18–related cervical intraepithelial neoplasia (CIN) 1–3 or…”
Get full text

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16–26 Years by Wheeler, Cosette M., Kjaer, Susanne K., Sigurdsson, Kristján, Iversen, Ole-Erik, Hernandez-Avila, Mauricio, Perez, Gonzalo, Brown, Darron R., Koutsky, Laura A., Tay, Eng Hseon, García, Patricia, Ault, Kevin A., Garland, Suzanne M., Leodolter, Sepp, Olsson, Sven-Eric, Tang, Grace W. K., Ferris, Daron G., Paavonen, Jorma, Steben, Marc, Bosch, F. Xavier, Dillner, Joakim, Joura, Elmar A., Kurman, Robert J., Majewski, Slawomir, Muñoz, Nubia, Myers, Evan R., Villa, Luisa L., Taddeo, Frank J., Roberts, Christine, Tadesse, Amha, Bryan, Janine, Lupinacci, Lisa C., Giacoletti, Katherine E. D., James, Margaret, Vuocolo, Scott, Hesley, Teresa M., Barr, Eliav

“…BackgroundWe evaluated the impact of a quadrivalent human papillomavirus (HPV) vaccine on infection and cervical disease related to 10 nonvaccine HPV types…”
Get full text

Impact of an HPV6/11/16/18 L1 virus‐like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection by Haupt, Richard M., Wheeler, Cosette M., Brown, Darron R., Garland, Suzanne M., Ferris, Daron G., Paavonen, Jorma A., Lehtinen, Matti O., Steben, Marc, Joura, Elmar A., Giacoletti, Katherine E. D., Radley, David R., James, Margaret K., Saah, Alfred J., Sings, Heather L.

“…The impact of a human papillomavirus (HPV) vaccine on development of cervical intraepithelial neoplasia grade 2‐3 or adenocarcinoma in situ (CIN2‐3/AIS) in…”
Get full text

Using proportion of similar response to evaluate correlates of protection for vaccine efficacy by Giacoletti, Katherine ED, Heyse, Joseph

“…A question of interest in many vaccine clinical development programmes is whether vaccine-induced serum antibody level can be used as a correlate of vaccine…”
Get full text

Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women by Muñoz, Nubia, Kjaer, Susanne K., Sigurdsson, Kristján, Iversen, Ole-Erik, Hernandez-Avila, Mauricio, Wheeler, Cosette M., Perez, Gonzalo, Brown, Darron R., Koutsky, Laura A., Tay, Eng Hseon, Garcia, Patricía J., Ault, Kevin A., Garland, Suzanne M., Leodolter, Sepp, Olsson, Sven-Eric, Tang, Grace W. K., Ferris, Daron G., Paavonen, Jorma, Steben, Marc, Bosch, F. Xavier, Dillner, Joakim, Huh, Warner K., Joura, Elmar A., Kurman, Robert J., Majewski, Slawomir, Myers, Evan R., Villa, Luisa L., Taddeo, Frank J., Roberts, Christine, Tadesse, Amha, Bryan, Janine T., Lupinacci, Lisa C., Giacoletti, Katherine E. D., Sings, Heather L., James, Margaret K., Hesley, Teresa M., Barr, Eliav, Haupt, Richard M.

“…Background The impact of the prophylactic vaccine against human papillomavirus (HPV) types 6, 11, 16, and 18 (HPV6/11/16/18) on all HPV-associated genital…”
Get full text

HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine by Joura, Elmar A, Kjaer, Susanne K, Wheeler, Cosette M, Sigurdsson, Kristján, Iversen, Ole-Erik, Hernandez-Avila, Mauricio, Perez, Gonzalo, Brown, Darron R, Koutsky, Laura A, Tay, Eng Hseon, García, Patricia, Ault, Kevin A, Garland, Suzanne M, Leodolter, Sepp, Olsson, Sven-Eric, Tang, Grace W.K, Ferris, Daron G, Paavonen, Jorma, Lehtinen, Matti, Steben, Marc, Bosch, Xavier, Dillner, Joakim, Kurman, Robert J, Majewski, Slawomir, Muñoz, Nubia, Myers, Evan R, Villa, Luisa L, Taddeo, Frank J, Roberts, Christine, Tadesse, Amha, Bryan, Janine, Lupinacci, Lisa C, Giacoletti, Katherine E.D, Lu, Shuang, Vuocolo, Scott, Hesley, Teresa M, Haupt, Richard M, Barr, Eliav

“…Abstract The efficacy of the quadrivalent Human Papillomavirus (HPV) vaccine is thought to be mediated by humoral immunity. We evaluated the correlation…”
Get full text

M-M-R®II manufactured using recombinant human albumin (rHA) and M-M-R®II manufactured using human serum albumin (HSA) exhibit similar safety and immunogenicity profiles when administered as a 2-dose regimen to healthy children by Wiedmann, Richard T, Reisinger, Keith S, Hartzel, Jonathan, Malacaman, Edgardo, Senders, Shelly D, Giacoletti, Katherine E.D, Shaw, Eric, Kuter, Barbara J, Schödel, Florian, Musey, Luwy K

“…Highlights • M-M-R®II manufactured using either rHA or HSA was administered to healthy children 12–18 months and 3–4 years of age. • M-M-R®II manufactured…”
Get full text

M-M-R?IImanufactured using recombinant human albumin (rHA) and M-M-R?IImanufactured using human serum albumin (HSA) exhibit similar safety and immunogenicity profiles when administered as a 2-dose regimen to healthy children by Wiedmann, Richard T, Reisinger, Keith S, Hartzel, Jonathan, Malacaman, Edgardo, Senders, Shelly D, Giacoletti, Katherine ED, Shaw, Eric, Kuter, Barbara J, Schödel, Florian, Musey, Luwy K

“…Prior to 2006, M-M-R®II(measles, mumps, and rubella virus vaccine live) was manufactured using human serum albumin (HSA) and each dose of the vaccine contained…”
Get full text

M-M-R registered II manufactured using recombinant human albumin (rHA) and M-M-R registered II manufactured using human serum albumin (HSA) exhibit similar safety and immunogenicity profiles when administered as a 2-dose regimen to healthy children by Wiedmann, Richard T, Reisinger, Keith S, Hartzel, Jonathan, Malacaman, Edgardo, Senders, Shelly D, Giacoletti, Katherine ED, Shaw, Eric, Kuter, Barbara J, Schodel, Florian, Musey, Luwy K

“…Prior to 2006, M-M-R registered II (measles, mumps, and rubella virus vaccine live) was manufactured using human serum albumin (HSA) and each dose of the…”
Get full text